CPT® Code 81281

Official Description

Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); known familial sequence variant

Common Language Description

Molecular genetic testing is a critical procedure used to identify specific gene mutations that are responsible for long QT syndrome (LQTS), a rare and inherited cardiac condition characterized by delayed repolarization of the heart. This condition is particularly sensitive to adrenergic stimulation, which can occur during activities such as exercise or excitement. The presence of certain mutations in genes associated with LQTS can lead to a prolongation of the ventricular action potential and an extended QT interval on an electrocardiogram (ECG). Individuals diagnosed with LQTS face an increased risk of developing irregular heart rhythms, experiencing cardiac palpitations, having syncopal episodes (fainting), and potentially suffering sudden cardiac death due to ventricular fibrillation. The genetic mutations associated with LQTS can be inherited in an autosomal dominant or autosomal recessive manner. In some cases, the more severe recessive phenotypes may also be linked to additional physical anomalies such as syndactyly, which is characterized by fused fingers or toes, and congenital neural deafness. The testing process involves a full sequence analysis, which compares segments of genes to identify similarities or differences, thereby elucidating relationships among them. This analysis also examines intrinsic features of the genes to locate active sites and post-translational modification sites, as well as the distribution of introns, exons, and regulatory elements. Genetic markers are identified through the detection of point mutations or single nucleotide polymorphisms (SNPs). The most prevalent mutation associated with LQTS, known as LQT1, is located on the KCNQ1 gene found on chromosome 11 and is present in approximately 30-35% of individuals diagnosed with this syndrome. The CPT® Code 81281 specifically pertains to the analysis of LQTS genes for known familial sequence variants. When a gene mutation causing LQTS or a related syndrome is identified in an individual, it is recommended that all first-degree relatives undergo molecular genetic testing. This testing can help identify common or familial variants among blood relatives and assess the risk factors for those who may carry the gene mutation. Additionally, other CPT® codes, such as 81280 and 81282, are used for full sequence analysis and for identifying deletion or duplication variants, respectively, further enhancing the understanding and management of long QT syndrome.

1. Indications

The molecular genetic testing for long QT syndrome gene analyses is indicated for the following conditions:

Known Familial Sequence Variant This testing is performed when an individual has been identified with a gene mutation causing long QT syndrome (LQTS) or another related syndrome. It is recommended for first-degree relatives to assess their risk of carrying the same mutation.

2. Procedure

The procedure for long QT syndrome gene analysis involves several key steps to ensure accurate identification of known familial variants:

Step 1: Sample Collection A biological sample, typically blood or saliva, is collected from the individual undergoing testing. This sample contains the DNA necessary for genetic analysis.
Step 2: DNA Extraction The DNA is extracted from the collected sample using standardized laboratory techniques. This process isolates the genetic material for further analysis.
Step 3: Genetic Analysis The extracted DNA is subjected to molecular genetic testing specifically targeting known familial sequence variants associated with long QT syndrome. This may involve techniques such as polymerase chain reaction (PCR) and sequencing to identify specific mutations.
Step 4: Data Interpretation The results of the genetic analysis are interpreted by qualified geneticists or laboratory professionals. They compare the individual's genetic data against known variants to determine if a familial mutation is present.
Step 5: Reporting Results The findings are compiled into a report that details the presence or absence of the known familial variant. This report is then communicated to the healthcare provider for further discussion with the patient and their family.

3. Post-Procedure

After the genetic testing procedure, individuals may receive counseling regarding the implications of the test results. If a known familial variant is identified, first-degree relatives may be advised to undergo testing to assess their risk. Additionally, healthcare providers may discuss potential monitoring strategies and lifestyle modifications to manage the risk of arrhythmias associated with long QT syndrome. Follow-up appointments may be scheduled to review the results and any necessary next steps in care or management.

Short Descr	LONG QT SYND KNOWN FAM VAR
Medium Descr	LONG QT SYNDROME ANAL KNOWN FAMILIAL SEQUENCE
Long Descr	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); known familial sequence variant
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	9 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Service Paid under Fee Schedule or Payment System other than OPPS
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T1H - Lab tests - other (non-Medicare fee schedule)
MUE	Not applicable/unspecified.
CCS Clinical Classification	234 - Pathology